WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H534655
CAS#: 151096-09-2 (free base)
Description: Moxifloxacin is a fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.
Hodoodo Cat#: H534655
Name: Moxifloxacin
CAS#: 151096-09-2 (free base)
Chemical Formula: C21H24FN3O4
Exact Mass: 401.18
Molecular Weight: 401.438
Elemental Analysis: C, 62.83; H, 6.03; F, 4.73; N, 10.47; O, 15.94
Related CAS #: 151096-09-2 (free base) 186826-86-8 (HCl) 192927-63-2 (HCl hydrate)
Synonym: Moxifloxacin
IUPAC/Chemical Name: 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
InChi Key: FABPRXSRWADJSP-MEDUHNTESA-N
InChi Code: InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1
SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 401.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ferreira KSA, Santos BMAD, Lucena NP, Ferraz MS, Carvalho RSF, Duarte Júnior AP, Magalhães NSS, Lira RPC. Ocular delivery of moxifloxacin-loaded liposomes. Arq Bras Oftalmol. 2018 Nov./Dec.;81(6):510-513. doi: 10.5935/0004-2749.20180090. Epub 2018 Sep 13. PMID: 30231158.
2: Leung EH, Gibbons A, Stout JT, Koch DD. Intracameral moxifloxacin for endophthalmitis prophylaxis after cataract surgery: Cost-effectiveness analysis. J Cataract Refract Surg. 2018 Aug;44(8):971-978. doi: 10.1016/j.jcrs.2018.05.022. Epub 2018 Jul 23. PMID: 30049565.
3: Arshinoff SA, Modabber M. Dose and administration of intracameral moxifloxacin for prophylaxis of postoperative endophthalmitis. J Cataract Refract Surg. 2016 Dec;42(12):1730-1741. doi: 10.1016/j.jcrs.2016.10.017. PMID: 28007104.
4: Xu P, Chen H, Xu J, Wu M, Zhu X, Wang F, Chen S, Xu J. Moxifloxacin is an effective and safe candidate agent for tuberculosis treatment: a meta-analysis. Int J Infect Dis. 2017 Jul;60:35-41. doi: 10.1016/j.ijid.2017.05.003. Epub 2017 May 8. PMID: 28495364.
5: Lee S, Lee JH, Wang T, Jang WH, Yoon Y, Kim B, Jun YW, Kim MJ, Kim KH. Three- photon tissue imaging using moxifloxacin. Sci Rep. 2018 Jun 20;8(1):9415. doi: 10.1038/s41598-018-27371-8. PMID: 29925864; PMCID: PMC6010410.
6: Zhou S, Hunt KM, Grewal AS, Brothers KM, Dhaliwal DK, Shanks RMQ. Release of Moxifloxacin From Corneal Collagen Shields. Eye Contact Lens. 2018 Nov;44 Suppl 2(Suppl 2):S143-S147. doi: 10.1097/ICL.0000000000000421. PMID: 28945653; PMCID: PMC5862718.
7: Bennett AC, Bennett CL, Witherspoon BJ, Knopf KB. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administration and the European Medicines Agency. Expert Opin Drug Saf. 2019 Nov;18(11):1055-1063. doi: 10.1080/14740338.2019.1665022. Epub 2019 Sep 18. PMID: 31500468.
8: Al Omari MM, Jaafari DS, Al-Sou'od KA, Badwan AA. Moxifloxacin hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:299-431. doi: 10.1016/B978-0-12-800173-8.00007-6. PMID: 24794910.
9: Kula Atik T, Ispir E, Aytekin A, Turhan U, Yeniiz E, Tas D, Bedir O. Moxifloxacin-induced neutropenia in 26-year-old man. J Infect Dev Ctries. 2018 Oct 31;12(10):922-925. doi: 10.3855/jidc.10212. PMID: 32004163.
10: Fily F, Jolivet-Gougeon A, Polard E, Gicquel T, Dupont M, Verdier MC, Arvieux C. Moxifloxacin-rifampicin combination for the treatment of non- staphylococcal Gram-positive orthopedic implant-related infections. Med Mal Infect. 2019 Oct;49(7):540-544. doi: 10.1016/j.medmal.2019.06.008. Epub 2019 Jul 3. PMID: 31277834.
